ArticleJournal of controlled release : official journal of the Controlled Release Society2015
SOD1 nanozyme salvages ischemic brain by locally protecting cerebral vasculature.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 79 citations in OpenAlex.
- Nanotechnology-donated ischemic stroke therapeutics: evolving strategies from the basic to the cutting-edge.Theranostics · 2026Review
- MOF-Engineered Platelet-Mimicking Nanocarrier-Encapsulated Cascade Enzymes for ROS Scavenging and Anti-Inflammation in Cerebral Ischemia-Reperfusion Injury.Pharmaceutics · 2025Article
- Article
- Transduction of jellyfish superoxide dismutase mediated by TAT peptide ameliorates HScientific reports · 2024Article
- Application of Nanozymes and its Progress in the Treatment of Ischemic Stroke.Translational stroke research · 2024Review
- A Bioinspired Manganese-Organic Framework Ameliorates Ischemic Stroke through its Intrinsic Nanozyme Activity and Upregulating Endogenous Antioxidant Enzymes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Stimuli-Responsive Nanotherapeutics for Treatment and Diagnosis of Stroke.Pharmaceutics · 2023Review
- Nanotechnology in Stroke: New Trails with Smaller Scales.Biomedicines · 2023Review
- Copper homeostasis and copper-induced cell death in the pathogenesis of cardiovascular disease and therapeutic strategies.Cell death & disease · 2023Review
- Mitochondria-containing extracellular vesicles (EV) reduce mouse brain infarct sizes and EV/HSP27 protect ischemic brain endothelial cultures.Journal of controlled release : official journal of the Controlled Release Society · 2023Article
- PEG-Free Polyion Complex Nanocarriers for Brain-Derived Neurotrophic Factor.Pharmaceutics · 2022Article
- Progresses and Prospects of Neuroprotective Agents-Loaded Nanoparticles and Biomimetic Material in Ischemic Stroke.Frontiers in cellular neuroscience · 2022Review
- Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance.Nature biomedical engineering · 2021Article
- Article
- The Role of Nanomaterials in Stroke Treatment: Targeting Oxidative Stress.Oxidative medicine and cellular longevity · 2021Review
- Improvement in the Pharmacological Profile of Copper Biological Active Complexes by Their Incorporation into Organic or Inorganic Matrix.Molecules (Basel, Switzerland) · 2020Review
- Understanding the in vivo Fate of Advanced Materials by Imaging.Advanced functional materials · 2020Article
- Microarray and bioinformatics analysis of circular RNAs expression profile in traumatic lung injury.Experimental and therapeutic medicine · 2020Article
- Biomaterials to Neuroprotect the Stroke Brain: A Large Opportunity for Narrow Time Windows.Cells · 2020Review
- Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders.Molecules (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Copper/zinc superoxide dismutase (CuZnSOD; SOD1) is widely considered as a potential therapeutic candidate for pathologies involving oxidative stress, but its application has been greatly hindered by delivery issues. In our previous study, nanoformulated SOD1 (cl-nanozyme) was shown to decrease infarct volume and improve sensorimotor functions after a single intravenous (IV) injection in a rat middle cerebral artery occlusion (MCAO) model of ischemia/reperfusion (I/R) injury (stroke). However, it remained unclear how cl-nanozyme was able to deliver SOD1 to the brain and exert therapeutic efficacy. The present study aims to answer this question by exploring micro-distribution pattern of cl-nanozyme in the rat brain after stroke. Immunohistochemistry studies demonstrated cl-nanozyme co-localization with fibrin along damaged arteries and capillaries in the ischemic hemisphere. We further found that cl-nanozyme can be cross-linked into thrombi formed after I/R injury in the brain, and this effect is independent of animal species (rat/mouse) used for modeling I/R injury. This work is also the first report reinforcing therapeutic potential of cl-nanozyme in a well-characterized mouse MCAO model of I/R injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.